Valuation: Scholar Rock Holding Corporation

Market Cap 6.23B 5.45B 5.12B 4.67B 8.77B 596B 8.77B 61.45B 23.71B 304B 23.41B 22.9B 981B P/E 2026 *
-15.6x
P/E 2027 * -19.7x
Enterprise Value 5.92B 5.17B 4.86B 4.44B 8.32B 566B 8.33B 58.33B 22.51B 289B 22.22B 21.74B 931B EV / Sales 2026 *
903x
EV / Sales 2027 * 41.2x
Free-Float
99.23%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Scholar Rock Holding Corporation

1 day+6.29%
1 week+2.38%
Current month-9.88%
1 month-9.40%
3 months+4.07%
6 months+14.67%
Current year+16.21%
1 week 45.88
Extreme 45.875
51.68
1 month 45.88
Extreme 45.875
61.76
Current year 38.75
Extreme 38.75
61.76
1 year 27.07
Extreme 27.07
61.76
3 years 6.18
Extreme 6.18
61.76
5 years 4.32
Extreme 4.325
61.76
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 2025-04-26
Director of Finance/CFO 62 2025-04-26
Chief Operating Officer 58 2025-04-26
Director TitleAgeSince
Chairman 59 2017-06-30
Director/Board Member 53 2014-07-31
Director/Board Member 78 2016-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
7/1/26 Sell

Director

-2,544 0.0022%
7/1/26 Sell

Director

-5,446 0.0047%
7/1/26 Sell

Director

-3,053 0.0027%
Change 5-day change 1-year change 3-year change Capi.($)
+6.29%+2.38%+57.12%+704.87% 5.87B
-0.07%+7.14%+53.95%+111.00% 74.33B
-1.45%-0.40%+35.52%+79.18% 62.26B
+0.38%+5.93%+33.92%+21.05% 27.72B
-0.15%+0.75%-16.69%+361.67% 26.42B
+2.93%+4.32%+2.18%-3.60% 24.62B
+0.84%+6.00%+25.53%-9.89% 20.72B
-0.94%+5.43%-5.43%+522.96% 15.1B
+0.87%-3.73%+159.95%+327.53% 15.01B
+1.63%+2.20%+46.92%+170.72% 14.18B
Average +1.04%+2.44%+39.30%+228.55% 28.62B
Weighted average by Cap. +0.22%+2.95%+37.11%+148.12%

Financials

2026 *2027 *
Net sales 6.55M 5.73M 5.38M 4.91M 9.22M 626M 9.22M 64.59M 24.92M 320M 24.61M 24.07M 1.03B 141M 124M 116M 106M 199M 13.51B 199M 1.39B 538M 6.9B 531M 519M 22.25B
Net income -429M -375M -352M -321M -603M -40.99B -603M -4.23B -1.63B -20.94B -1.61B -1.58B -67.49B -360M -314M -295M -270M -506M -34.39B -506M -3.55B -1.37B -17.56B -1.35B -1.32B -56.61B
Net Debt -316M -277M -260M -237M -445M -30.25B -445M -3.12B -1.2B -15.45B -1.19B -1.16B -49.81B -410M -359M -337M -308M -577M -39.23B -577M -4.05B -1.56B -20.04B -1.54B -1.51B -64.59B
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
26-09-22 US$51.19 +6.29% 3,748,523
26-09-21 US$48.16 +3.24% 2,904,214
26-09-18 US$46.65 -4.83% 3,253,096
26-09-17 US$49.02 -0.71% 3,485,708
26-09-16 US$49.37 -1.26% 3,657,746
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
51.19USD
Average target price
70.38USD
Spread / Average Target
+37.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRRK Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!